The worldwide medical impact of hepatitis D virus infection: Focus to Central Asia

Basit Öğe Kaydı
dc.authorid0000-0002-8909-2102
dc.authorid0000-0002-7684-1768
dc.authorid0000-0002-9513-5324
dc.contributor.authorAghayeva, Gulnara
dc.contributor.authorRizzetto, Mario
dc.contributor.authorÖrmeci, Necati
dc.contributor.authorTurcanu, Adela
dc.contributor.authorAbbas, Zaigham
dc.contributor.authorBedewy, Essam
dc.contributor.editorSatapathy, Sanjaya K.
dc.contributor.editorAl-Mahtab, Mamun
dc.contributor.editorSingh, Shivaram Prasad
dc.contributor.editorAkbar, Sheikh Mohammad Fazle
dc.contributor.editorAla, Aftab
dc.contributor.editorSchiano, Thomas D.
dc.date.accessioned2024-11-29T13:41:21Z
dc.date.available2024-11-29T13:41:21Z
dc.date.issued2025
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractHepatitis D virus (HDV) requires hepatitis B virus (HBV) for its replication. Concurrent infection with HBV and HDV results in more severe disease outcomes than infection with HBV alone, inducing cirrhosis, fulminant hepatitis, and hepatocellular carcinoma, and representing a significant cause of global mortality. Central Asia remains an area of high HDV prevalence but local features of the infection were poorly detailed in the past. Until recently, interferon has represented the only treatment option in patients with chronic hepatitis D; however, it is associated with low efficacy and a high burden of side effects. The discovery of the entry inhibitor bulevirtide has represented a breakthrough in HDV treatment. Other compounds (i.e., lonafarnib, new anti-hepatitis B virus drugs) are under development to provide alternative or combined strategies for HDV cure.
dc.identifier.citationAghayeva, G., Rizzetto, M., Örmeci, N., Turcanu, A., Abbas, Z., & Bedewy, E. (2025). The worldwide medical impact of hepatitis D virus infection: Focus to Central Asia. S. K. Satapathy, M. Al-Mahtab, S. P. Singh, S. M. F. Akbar, A. Ala, T. D. Schiano, (Eds). Hepatology: An Evidence-Based Clinical Compendium, (pp. 655-673). London: Academic Press.
dc.identifier.doi10.1016/B978-0-443-26710-9.00023-7
dc.identifier.endpage673
dc.identifier.isbn9780443267109
dc.identifier.isbn9780443300523
dc.identifier.startpage655
dc.identifier.urihttps://hdl.handle.net/20.500.13055/860
dc.institutionauthorÖrmeci, Necati
dc.institutionauthorid0000-0002-8909-2102
dc.language.isoen
dc.publisherAcademic Press
dc.relation.ispartofHepatology: An Evidence-Based Clinical Compendium
dc.relation.publicationcategoryKitap Bölümü - Uluslararası
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCentral Asia
dc.subjectHepatitis D Virus (HDV)
dc.subjectHepatitis B Virus (HBV)
dc.titleThe worldwide medical impact of hepatitis D virus infection: Focus to Central Asia
dc.typeBook Chapter
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Kapalı Erişim
Ä°sim:
Tam Metin / Full Text
Boyut:
7.1 MB
Biçim:
Adobe Portable Document Format
Ä°ndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
Ä°sim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
Ä°ndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Koleksiyonu